Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TALWIN 50 vs ALFENTA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Pentazocine is a mixed agonist-antagonist opioid analgesic with activity at kappa opioid receptors (agonist) and mu opioid receptors (partial agonist/antagonist). It also exhibits weak antagonistic activity at mu receptors, which reduces abuse liability but may precipitate withdrawal in opioid-dependent patients.
μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.
Moderate to severe pain,Preoperative or preanesthetic medication,Supplement to surgical anesthesia
Induction and maintenance of anesthesia,Analgesic supplement during surgical procedures,Intravenous use for monitored anesthesia care (MAC)
50 mg orally every 3-4 hours as needed; maximum 600 mg per day.
Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.
Terminal elimination half-life is 2-3 hours. In patients with hepatic impairment, half-life may extend to 5-8 hours; in renal impairment, minimal change, but active metabolite accumulation may occur.
Terminal elimination half-life: 90–111 minutes (1.5–1.85 hours); prolonged in hepatic impairment.
Primarily hepatic via CYP3A4 and CYP2C19; also undergoes glucuronidation. Metabolites include hydroxylated and conjugated forms, which are excreted renally.
Hepatic via CYP3A4 to inactive metabolites; major metabolite is desmethylalfentanil (inactive).
Primarily renal (60-70% as unchanged drug and conjugates), with 20-30% biliary/fecal elimination. Approximately 5-10% excreted in feces via bile.
Primarily renal (urinary) elimination as metabolites; approximately 80% recovered in urine, 20% in feces.
Approximately 60% bound to plasma proteins, primarily albumin.
Approximately 92% bound, primarily to alpha-1 acid glycoprotein and albumin.
5-8 L/kg, indicating extensive tissue distribution and high accumulation in tissues (e.g., liver, kidney, lungs).
0.5–1.0 L/kg; reflects moderate tissue distribution; higher Vd in neonates and elderly.
Oral: 17-20% due to first-pass metabolism; Intramuscular/Subcutaneous: >90%.
Intravenous: 100%; intramuscular: approximately 90%; intrathecal: approximately 10% (due to systemic absorption following spinal administration).
GFR 30-50 m L/min: 50 mg every 6 hours; GFR 10-29 m L/min: 50 mg every 8 hours; GFR <10 m L/min: 50 mg every 12 hours.
No specific dose adjustment is recommended for renal impairment; however, alfentanil is primarily metabolized in the liver and its pharmacokinetics are not significantly altered in renal failure.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25%; Child-Pugh C: reduce dose by 50% or avoid use.
In hepatic impairment (Child-Pugh class A, B, C): Reduce dose by 50% and titrate carefully due to prolonged elimination half-life. Consider lower initial doses and extended dosing intervals.
Not recommended for pediatric use due to safety concerns.
Children (1-12 years): Induction of anesthesia: 10-20 mcg/kg IV; maintenance: 5-10 mcg/kg IV or infusion 0.5-1 mcg/kg/min. For neonates and infants: Dose individualization required; titrate to effect.
Initiate at 25 mg every 4 hours and titrate cautiously; monitor for respiratory depression and constipation.
Elderly patients (>65 years): Reduce initial dose by 30-50% and administer slowly. Due to decreased clearance and increased sensitivity, lower infusion rates (e.g., 0.3-0.5 mcg/kg/min) may be needed.
Risk of serious or fatal respiratory depression, particularly in elderly or debilitated patients; risk of addiction, abuse, and misuse; accidental ingestion may cause fatal overdose especially in children; neonatal opioid withdrawal syndrome with prolonged use during pregnancy; risks from concomitant use with CNS depressants (e.g., benzodiazepines) that may lead to profound sedation, respiratory depression, coma, and death.
Risk of respiratory depression, particularly in elderly or debilitated patients. Concomitant use with benzodiazepines or other CNS depressants may cause profound sedation, respiratory depression, coma, and death.
Respiratory depression; opioid-induced hyperalgesia; hypotension; increased intracranial pressure; seizure risk; biliary spasm; severe injection site reactions (e.g., induration, fibrosis, necrosis); risk of withdrawal in opioid-dependent patients; adrenal insufficiency; severe hypotension; impaired mental/physical abilities; caution in renal/hepatic impairment; avoid in pregnancy unless benefit outweighs risk; not recommended for children under 12 years.
Respiratory depression; abuse potential; hypotension; bradycardia; muscle rigidity; serotonin syndrome with concurrent serotonergic drugs; adrenal insufficiency; risk of withdrawal with prolonged use.
Significant respiratory depression; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction (e.g., paralytic ileus); hypersensitivity to pentazocine or any component of the formulation; concurrent use of MAOIs or within 14 days of MAOI cessation; in patients who are physically dependent on opioids and are not in a controlled treatment setting (risk of precipitated withdrawal).
Hypersensitivity to alfentanil or any component; significant respiratory insufficiency; severe asthma; paralytic ileus; concurrent use of MAOIs (or within 14 days); acute or postoperative pain management in children (except for procedural sedation).
No specific food interactions have been reported. Avoid alcohol consumption due to additive CNS depression. Grapefruit juice may inhibit metabolism of pentazocine (theoretical), but clinical significance is unclear. Maintain a balanced diet; no restrictions necessary.
No known interactions with food. However, grapefruit juice may increase alfentanil serum concentrations due to CYP3A4 inhibition; avoid concurrent consumption.
First trimester: Limited human data; animal studies show no evidence of teratogenicity. Second and third trimesters: Prolonged use may cause neonatal opioid withdrawal syndrome; avoid near term as respiratory depression may occur.
Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effects were observed at clinically relevant doses; however, high doses caused embryotoxicity and increased fetal mortality. Trimester-specific risks: First trimester - potential for minor malformations based on limited human data; second trimester - possible risk if used chronically; third trimester - prolonged use may lead to neonatal respiratory depression, withdrawal syndrome, or opioid dependence. Use only if benefits outweigh risks.
Excreted in breast milk in low concentrations. M/P ratio not established. Use with caution; monitor infant for sedation and respiratory depression.
Alfentanil is excreted into human breast milk in low concentrations. The milk-to-plasma (M/P) ratio is approximately 0.3. Estimated infant dose is <1% of maternal weight-adjusted dose, which is considered clinically insignificant. However, due to potential for neonatal opioid effects, caution is advised; monitor infant for drowsiness, respiratory depression, and feeding difficulties. Consider alternative analgesics with established safety profiles, such as acetaminophen or ibuprofen, for lactation.
No standard dose adjustment recommended for pregnancy. However, increased clearance during pregnancy may require higher doses or more frequent administration to achieve analgesia; titrate to effect with close monitoring.
Pregnancy can alter pharmacokinetics of alfentanil. Increased plasma volume and distribution may require higher doses to achieve same effect, while decreased plasma protein binding may increase free fraction, potentiating effects. Alpha-1-acid glycoprotein levels change in pregnancy, affecting binding. In third trimester, clearance may be increased by up to 50% due to enhanced hepatic metabolism. Therefore, dose adjustments may be needed: consider starting at low dose and titrating to effect, with close monitoring. For intravenous administration, typical adult doses (5-20 μg/kg) may need adjustments; no standard pregnancy-specific dosing exists. Use the lowest effective dose for the shortest duration. In labor, avoid high doses prior to delivery due to risk of neonatal respiratory depression.
Talwin (pentazocine) is a mixed agonist-antagonist opioid analgesic. It can precipitate withdrawal in opioid-dependent patients due to its partial antagonist activity at mu receptors. Monitor for respiratory depression, which may not be fully reversed by naloxone. Avoid in patients with acute MI or coronary insufficiency as it can increase cardiac workload. Use with caution in renal impairment as accumulation of active metabolites may occur.
Alfentanil is a potent, rapid-onset, short-acting opioid analgesic used primarily for induction and maintenance of anesthesia. Due to its high protein binding (90%) and rapid redistribution, it has a shorter duration of action than fentanyl, making it suitable for brief, painful procedures. It undergoes hepatic metabolism via CYP3A4, so concomitant use with CYP3A4 inhibitors like ketoconazole or erythromycin can prolong its effects. Use caution in elderly or hypovolemic patients due to increased risk of hypotension. Naloxone reverses respiratory depression. Alfentanil is 5-10 times less potent than fentanyl.
Do not take Talwin if you have been using other opioids (e.g., morphine, codeine) as it can cause severe withdrawal symptoms.,This medication may cause dizziness, drowsiness, or blurred vision. Avoid driving or operating machinery until you know how it affects you.,Do not consume alcohol while taking Talwin as it increases the risk of severe sedation and respiratory depression.,Take Talwin exactly as prescribed. Do not increase dose or frequency without consulting your doctor.,If you are pregnant, planning to become pregnant, or breastfeeding, discuss with your doctor before use.,Store Talwin at room temperature away from moisture and heat. Keep out of reach of children.,Do not share this medication with others. It is a controlled substance and can cause dependence.
This medication is given only by a healthcare professional in a hospital or surgical setting.,You may feel drowsy, dizzy, or nauseated after receiving this drug.,Report any difficulty breathing or slow heart rate to your healthcare provider immediately.,Avoid alcohol and sedatives for 24 hours after administration, as they can increase side effects.,Do not drive or operate machinery until the effects have fully worn off.
No interactions on record
"Propantheline, an anticholinergic agent, can competitively antagonize muscarinic acetylcholine receptors, potentially reducing gastrointestinal motility and secretion. Alfentanil, a mu-opioid receptor agonist, also decreases gastrointestinal motility through central and peripheral opioid receptors. Concomitant use may synergistically inhibit peristalsis, leading to severe constipation, paralytic ileus, or delayed gastric emptying, which can increase the risk of aspiration and complicate anesthesia recovery."
"Alfentanil, a potent opioid analgesic, can cause significant hypotension and respiratory depression. When combined with furosemide, a loop diuretic that reduces blood volume and vascular resistance, there is a synergistic decrease in blood pressure, which may precipitate cardiovascular collapse, especially in patients with compromised circulatory reserves. Additionally, furosemide may enhance the sedative and respiratory depressant effects of alfentanil, leading to increased risk of respiratory acidosis and altered mental status."
"Alfentanil, a potent mu-opioid receptor agonist, can enhance the bradycardic effects of nebivolol, a beta-1 selective blocker with additional nitric oxide-mediated vasodilation. The combination may lead to excessive slowing of heart rate, reduced cardiac output, and potential hemodynamic instability, particularly in patients with underlying cardiac conduction abnormalities or hypovolemia."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TALWIN 50 vs ALFENTA, answered by our medical review team.
TALWIN 50 is a Opioid Analgesic that works by Pentazocine is a mixed agonist-antagonist opioid analgesic with activity at kappa opioid receptors (agonist) and mu opioid receptors (partial agonist/antagonist). It also exhibits weak antagonistic activity at mu receptors, which reduces abuse liability but may precipitate withdrawal in opioid-dependent patients.. ALFENTA is a Opioid Analgesic that works by μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TALWIN 50 and ALFENTA depend on the specific clinical indication. These are both Opioid Analgesic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TALWIN 50 is: 50 mg orally every 3-4 hours as needed; maximum 600 mg per day.. The standard adult dose of ALFENTA is: Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TALWIN 50 and ALFENTA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TALWIN 50 is classified as Category C. First trimester: Limited human data; animal studies show no evidence of teratogenicity. Second and third trimesters: Prolonged use may cause neonatal opioid withdrawal syndrome; av. ALFENTA is classified as Category C. Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effect. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.